Discuss of clinic pathology and biology features and factor of prognostic affect in triple negative breast cancer

doi:10.3877/cma.j.issn.1674-0793.2010.04.011

Abstract

Abstract:

Objective

To analyze the clinic pathology features and factor of prognosis affect in triple negative breast cancer(TNBC).

Methods

A total of 329 cases of operation and pathology approve, immune histochemistry determine HER-2, ER, PR and p53 by breast cancer been analyzed. The patients were divided into the TNBC group and the non-triple negative breast cancer group (NTNBC). The clinic pathologic and biology features of the two groups were compared. The 5-year survival was analyzed by Kaplan-Meier method.

Results

Of the 79.03% (260/329) had NTNBC. TNBC 20.97% (69/329), average was 42 years, prophase of catamenia 73.91%(51/69), p53(+) 44.93%(31/69), infiltration duct cancer 73.91%(52/69), T3(T>5 cm) 27.54%(19/69), Ⅲ stages 30.43%(21/69), histology grade 39.13%(27/69), lymph metastasis 55.07%(38/69), Ⅲ 24.64%(17/69), percentage of cases with after operation recur 27.54%(19/69), and beyond distract 18.84%(13/69), higher in the TNBC group than in the NTNBC group(P<0.05). The 5-year without tumor was 78.26%(54/69)in the TNBC group and 86.92%(226/260) in NTNBC group(P<0.05).

Conclusions

TNBC happens in female with prophase of catamenia. Compared with NTNBC, higher in p53(+), percentage of with TNBC has an increased possibility of local recurrence or distant metastasis in features of clinic pathology and biology, poorer of prognosis.

Key words: Breast Cancer, Triple Negative, Pathology, Prognosis

Yi ZHANG, Yan WANG, Yu-jun LI, Ming-zhi CAO, Jun LIANG. Discuss of clinic pathology and biology features and factor of prognostic affect in triple negative breast cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2010, 04(04): 336-340.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2010.04.011

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2010/V04/I04/336

Figures/Tables 6

References 11

1	Rakha EA, EISayed ME, Green AR，et al. Prognostic marker sin triple negative breast cancer. Cancer，2007，109(1):25-32.
2	Sorlie T, Perou C, Tibshirani R，et al. Gene expression pattems of breast carcinoma distingish tumor subclasses with clinical implications. Proc Natl Acad Sci USA，2001，98(8):10869-10874.
3	Cheang MC, Voduc D, Bajdik C，et al. Basal like breast cancer defined by five bio marker shas superior prognostic value than triple negative phenotype. Clin Cancer Res，2008，14(5):1368-1376.
4	Cleator S, Heller W, Coombes RC. Triple negative breast cancer: therapeutic options. Lancet Oncol，2007，8(3):235-244.
5	Shiu KK, Tan DS, ReisFilho JS. Development of therapeutic approaches to triple negative phenotype breast cancer.Expert Opin Ther Targets，2008，12(9):1123-1137.
6	Rottenberg S, Jaspers JE, Kersbergen A，et al. High sensitivity of BRCA 12 deficient mammary tumors to the PARP inhibitor AZD 2281l one and in combination with platinum drugs. Proc Natl Acad Sci USA，2008，105(44):17079-17084.
7	Dent R, Trudeau M, Pritchard KI，et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res，2007，13(15):4429-4434.
8	Haffty BG, Yang Q, Reiss M，et al. Loco regional relapse and distant metastasis in conservatively managed triple negative earliest age breast cancer. Clin Oncol，2006，24(36):5652-5657.
9	Elsheikh SE, Green AR, Rakha EA，et al. Caveolin 1 and Caveolin 2 are associated with breast cancer basal like and triple negative immune phenotype. Br Cancer，2008，99(2):327-334.
10	Livasy CA, Karaca G, Nanda R，et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma.Mod Pathol，2006，19(2):264-271.
11	Liedtke C, Mazouni C, Hess KR，et al. Response toneo adjuvant therapy and long term survival in patients with triple negative breast cancer. Clin Oncol，2008，26(8):1275-1281.

组别	HER-2	ER	PR	p53
阳性	179(54.41)	148(44.98)	114(34.65)	81(24.62)
阴性	150(45.59)	181(55.02)	215(65.35)	248(75.38)
χ²值	3.48	4.84	9.70	11.62
P值	?	?	<0.05	<0.05

组别	HER-2	ER	PR	p53
阳性	179(54.41)	148(44.98)	114(34.65)	81(24.62)
阴性	150(45.59)	181(55.02)	215(65.35)	248(75.38)
χ²值	3.48	4.84	9.70	11.62
P值	?	?	<0.05	<0.05

项目		TNBC组	NTNBC组	χ²值	P值
例数		69	260	?	?
年龄(岁)		?	?	9.91	0.032
?	<50	49(71.01)	113(43.46)	?	?
?	≥50	20(28.99)	147(56.54)	?	?
月经状况		?	?	9.24	0.038
?	绝经	18(26.09)	126(48.46)	?	?
?	未绝经	51(73.91)	134(51.54)	?	?
家族史		?	?	7.96	0.046
?	无肿瘤家族史	53(76.81)	198(76.15)	?	?
?	乳腺癌家族史	12(17.39)	27(10.38)	?	?
?	其他癌家族史	4(5.80)	35(13.46)	?	?
复发转移情况		?	?	8.36	0.034
?	局部复发	19(27.54)	34(13.08)	?	?
?	远处转移	13(18.84)	28(10.77)	?	?
随访情况		?	?	8.52	0.036
?	死亡	17(24.64)	34(13.08)	?	?
?	生存	52(75.36)	226(86.92)	?	?

项目		TNBC组	NTNBC组	χ²值	P值
例数		69	260	?	?
年龄(岁)		?	?	9.91	0.032
?	<50	49(71.01)	113(43.46)	?	?
?	≥50	20(28.99)	147(56.54)	?	?
月经状况		?	?	9.24	0.038
?	绝经	18(26.09)	126(48.46)	?	?
?	未绝经	51(73.91)	134(51.54)	?	?
家族史		?	?	7.96	0.046
?	无肿瘤家族史	53(76.81)	198(76.15)	?	?
?	乳腺癌家族史	12(17.39)	27(10.38)	?	?
?	其他癌家族史	4(5.80)	35(13.46)	?	?
复发转移情况		?	?	8.36	0.034
?	局部复发	19(27.54)	34(13.08)	?	?
?	远处转移	13(18.84)	28(10.77)	?	?
随访情况		?	?	8.52	0.036
?	死亡	17(24.64)	34(13.08)	?	?
?	生存	52(75.36)	226(86.92)	?	?

项目		TNBC组	NTNBC组	χ²值	P值
肿瘤大小(cm)		?	?	8.25	0.042
?	T1(T≤2)	11(15.94)	47(18.08)	?	?
?	T2（2<T≤5）	39(56.52)	162(62.30)	?	?
?	T3(T>5)	19(27.54)	51(19.62)	?	?
肿瘤分期		?	?	9.79	0.035
?	Ⅰ	9(13.04)	42(16.15)	?	?
?	Ⅱ	39(56.52)	169(65.00)	?	?
?	Ⅲ	21(30.43)	49(18.85)	?	?
淋巴结状态		?	?	12.57	0.025
?	阳性	38(55.07)	114(43.85)	?	?
?	阴性	31(44.92)	146(56.15)	?	?
淋巴结阳性(枚)		?	?	8.34	0.046
?	1～3	7(18.42)	34(29.82)	?	?
?	4～9	19(50.00)	51(44.74)	?	?
?	≥10	12(31.58)	29(25.44)	?	?
组织学分级		?	?	11.23	0.006
?	Ⅰ	9(13.04)	45(17.31)	?	?
?	Ⅱ	23(33.33)	176(67.69)	?	?
?	Ⅲ	27(39.13)	39(15.00)	?	?
病理类型		?	?	12.48	0.004
?	浸润性导管癌	51(73.91)	162(62.31)	?	?
?	髓样癌	10(14.49)	52(20.00)	?	?
?	浸润性特殊类型癌	8(11.59)	46(17.69)	?	?
p53表达		?	?	?	?
?	阳性	31(44.93)	50(19.23)	14.23	0.001
?	阴性	38(55.07)	210(80.77)	?	?

Please choose a citation manager

Content to export